Concentration of management resources in the cancer precision medicine-related business and a return to profitability
First written in FY2024-Q3. 5 of 7 entries say "Advanced", first in FY2025. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07AdvancedEarnings
「Cancer precision medicine business Revenue from the business amounted to ¥168 million, a decrease of ¥30 million year on year, due to the receipt of income from analysis services and other sources. In addition, mainly due to the recognition of cost of sales related to analysis services, including genetic analysis services such as whole-genome sequencing analysis, neoantigen analysis and neoantigen dendritic cell therapy, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis, operating loss was ¥17 million, compared with a loss of ¥21 million in the previous period.」
In the cancer precision medicine business, business revenue declined year on year, while operating loss narrowed from ¥21 million to ¥17 million. The business has not yet become profitable, but the narrowing of loss continued. - FY2026AdvancedAnnual report
「b. Cancer precision medicine business Business revenue was ¥806 million, an increase of ¥59 million year on year, due to income from analytical services and other sources. The operating loss was ¥55 million, compared with a loss of ¥90 million in the previous fiscal year, mainly due to the recording of cost of sales related to analytical services, including genetic analysis services such as whole-genome sequencing, neoantigen analysis and neoantigen dendritic cell therapy, as well as liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Revenue from the cancer precision medicine business increased to ¥806 million, while the operating loss narrowed from ¥90 million to ¥55 million. Although the business has not yet returned to profitability, revenue growth and loss reduction progressed in line with the profitability policy. - 2026-05-08AdvancedRevision of earnings forecasts
「Revenue from the business amounted to ¥806 million, an increase of ¥59 million year on year, due to the receipt of income from analysis services and other sources. In addition, mainly due to the recognition of cost of sales related to analysis services, including genetic analysis services such as whole-genome sequencing analysis, neoantigen analysis and neoantigen dendritic cell therapy, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis, operating loss was ¥55 million, compared with a loss of ¥90 million in the previous fiscal year.」
The increase in revenue and narrowing of operating loss in the cancer precision medicine business were reported. The business has not yet become profitable, but progress was made toward the profitability target. - FY2026-H1AdvancedAnnual report
「Cancer precision medicine business: Business revenue was ¥429 million, an increase of ¥207 million year on year, due to income from analytical services and other sources. The operating loss was ¥6 million, compared with a loss of ¥93 million in the previous fiscal year, mainly due to the recording of cost of sales related to analytical services, including genetic analysis services such as whole-genome sequencing, neoantigen analysis and neoantigen dendritic cell therapy, as well as liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business's revenue for the interim period increased to ¥429 million, while its operating loss narrowed from ¥93 million to ¥6 million. Although it has not yet returned to profitability, the results showed measurable improvement toward the profitability target. - FY2025AdvancedAnnual report
「The group has a policy of focusing on its cancer precision medicine business and aims to return it to profitability.」
The company continued to focus on the cancer precision medicine business and maintain its policy of returning it to profitability. Annual business revenue was ¥747 million and the operating loss was ¥90 million. Revenue increased and the loss narrowed year on year, but the business did not return to profitability. - FY2025-H1RestatedAnnual report
「In the clinical testing business within this segment, the company aims to make clinical testing available to more patients, including through orders from overseas for medical tourism and other purposes, by adding new clinical testing items based on blood specimens, making testing possible even when cancer tissue cannot be obtained.」
The company continues to focus on the cancer precision medicine business and maintain its policy of returning it to profitability, citing the addition of testing items using blood specimens, overseas orders, large-scale projects, and the introduction of new technologies and analytical instruments as means of improving order capacity and profit margins. - FY2024-Q3First statedAnnual report
「The group has a policy of focusing on its cancer precision medicine business and aims to return it to profitability.」
As measures to address the going-concern assumption, the company has clearly set out a policy of concentrating management resources on the cancer precision medicine business, expanding orders, improving profit margins, strengthening its management base through business investment and returning to profitability.